Dexamethasone 8 mg for Cancer-Related Fatigue in Inpatients with Advanced Cancer Undergoing Palliative Care: A Multicenter Phase II Trial

Tomofumi Miura, MD, PhD,1,* Ayumi Okizaki, RP, PhD,2 Hideaki Hasuo, MD, PhD,3 Eriko Satomi, MD,4 Keita Tagami, MD, PhD,5,ii Kengo Imai, MD,6 Takashi Kojima, MD,7 Hironaga Satake, MD, PhD,8 Hiroto Ishiki, MD,4 Akira Inoue, MD, PhD,5 and Takuhiro Yamaguchi, PhD9

Abstract

Objective: No standard treatment for cancer-related fatigue (CRF) for inpatients in a palliative care setting exists. The aim of this study was to validate the previous study-derived efficacy of dexamethasone 8 mg for CRF among inpatients in a palliative care setting.

Methods: Inpatients with moderate fatigue (≥4/10) were enrolled in a multicenter phase II trial. Dexamethasone 8 mg p.o. or 6.6 mg i.v. was administered for seven days and 4 mg p.o. or 3.3 mg i.v. for seven consecutive days. The primary endpoint was a threshold average change of Functional Assessment of Chronic Illness Therapy (FACIT)-fatigue subscale score of 3. The secondary endpoints were evaluated with the anorexia-cachexia subscale (ACS), and the Edmonton symptom assessment scale-revised Japanese version.

Results: A total of 32 patients were enrolled. On day 8, the mean change of FACIT-fatigue subscale from day 1 was 5.2 (95% confidence interval 0.8–10.0), in which the lower bound was above 0 but not above the prespecified threshold value of 3.0 (p = 0.72). Edmonton symptom assessment system (ESAS)-fatigue was significantly improved by day 3 (p = 0.02), but not on day 8 or day 15. ACS, physical well-being, and ESAS-lack of appetite significantly improved by day 8 and day 15. Adverse events were tolerable.

1Department of Palliative Medicine, National Cancer Center Hospital East, Kashiwa, Japan.
2Innovation Center for Supportive, Palliative and Psychosocial Care, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.
3Department of Psychosomatic Medicine, Kansai Medical University, Hirakata, Japan.
4Department of Palliative Medicine, National Cancer Center Hospital, Tokyo, Japan.
5Department of Palliative Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
6Seirei Hospice, Seirei Mikatahara General Hospital, Hamamatsu, Japan.
7Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
8Cancer Treatment Center, Kansai Medical University Hospital, Hirakata, Japan.
9Division of Biostatistics, Tohoku University Graduate School of Medicine, Sendai, Japan.

*ORCID ID (https://orcid.org/0000-0002-7031-7279).
iiORCID ID (https://orcid.org/0000-0001-8081-5979).

Address correspondence to: Tomofumi Miura, MD, PhD, Department of Palliative Medicine, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, 277-8577, Japan; E-mail: tomiura@east.ncc.go.jp

© Tomofumi Miura et al., 2021; Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative Commons License [CC-BY] (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Conclusion: This study showed that dexamethasone 8 mg failed to achieve the preset efficacy for CRF among inpatients in a palliative care setting. However, this treatment improved fatigue and would be an option for CRF.

jRCT (jRCTs031180068).

Keywords: appetite; cancer patients; cancer-related fatigue; dexamethasone; inpatient; palliative care

Introduction
Cancer-related fatigue (CRF) is observed in 50% to 70% of advanced cancer patients and is the most distressing symptom of terminally ill cancer patients. CRF is a multidimensional symptom and refractory to pharmacologic treatment. A double-blinded placebo-controlled randomized controlled trial (RCT) using a validated questionnaire among outpatients showed that dexamethasone 8 mg improved CRF. Another double-blinded placebo-controlled RCT reported that methyl prednisolone 32 mg improved CRF as a secondary endpoint among outpatients. Among inpatients with CRF and undergoing only palliative care, an observation study showed that a mean betamethasone concentration of 2.4 mg improved CRF using the numeric rating scale (NRS). In this observation study, palliative care physicians decided the dose of corticosteroids at each physician’s discretion. Although more dosage of dexamethasone might show more efficacy even in inpatients with CRF undergoing palliative care, there are no standard treatments for inpatients with CRF undergoing palliative care.

The aim of the phase II clinical trial is to reproduce the same efficacy of dexamethasone 8 mg for CRF among inpatients with CRF who were undergoing palliative care using a validated questionnaire.

Methods
A multicenter phase II study was conducted to validate the efficacy of dexamethasone 8 mg for CRF in inpatients in a palliative care setting. This study was conducted in accordance with the ethical standards of the Declaration of Helsinki, the Ethical Guidelines for Medical and Health Research Involving Human Subjects, and the Clinical Trials Act by an Ordinance of the Ministry of Health, Labor and Welfare in Japan. This study was approved by the National Cancer Center Hospital East (NCCE) Certified Review Board (CRB3180009) and registered in jRCT.

Clinical Palliative Care Program
The NCCE is one of five institutes in this study. NCCE is a high-volume cancer center, providing the best in cancer treatment and palliative care. NCCE has four palliative care programs: (1) outpatient clinics for cancer patients at any cancer stage, (2) palliative care consultation for cancer patients on the oncology floor, (3) an inpatient palliative care unit, and (4) consultation service for social or economic issues. Patients and caregivers are referred to these palliative care programs by oncologists or by their own request. NCCE has 8 palliative care physicians, 3 psycho-oncologists, and 52 certificated nurses involved in palliative care.

Kansai Medical University Hospital is an advanced cancer center hospital located in Osaka, a big city in western Japan. The palliative care center offers three main palliative care programs: (1) the outpatients clinics for cancer patients with any cancer stage, (2) palliative care consultation for cancer patients in the oncology floor, and (3) palliative care education for graduate students and community health care providers.

The National Cancer Center Hospital (NCCH) is a tertiary cancer center providing the best cancer treatments and palliative care. NCCH provides three palliative care programs: (1) the outpatients clinics for cancer patients with any cancer stage, (2) palliative care consultation for cancer patients in the oncology floor, and (3) consultation about any social or economic issues.

All programs were provided for five days a week. Patients and caregivers were referred to these palliative care programs by their own will or by oncologists. NCCH have 4 palliative care physicians, 4 psycho-oncologists, and 49 certificated nurses involved in palliative care.

Tohoku University Hospital (TUH) that belongs to Tohoku University Graduate School of Medicine has a high-volume palliative care division. TUH set three specialized palliative care services for any patients with any diseases in hospital: (1) outpatients clinics, (2) palliative care consultation for any inpatients, and (3) palliative care unit for cancer and HIV infection patients, and provided specialized palliative care outreach programs to the community and rural areas. Hospital-based outpatients clinic and consultation service were provided for five days a week and palliative care unit for seven days a week, and outreach program is
delivered daily in any areas by several health care providers. Patients and caregivers were referred to those specialized palliative care programs by their own will or any health care providers. TUH has 11 palliative care physicians, 2 psycho-oncologists, and 8 certificated nurses involved in our palliative care services.

The Seirei Mikatahara General Hospital is a 934-bed designated cancer hospital and providing cancer treatments and palliative care. It provides three palliative care programs: (1) the outpatients clinics for cancer patients, (2) palliative care consultation for inpatients, and (3) a 27-bed palliative care unit. All programs were provided for five days a week. Patients and caregivers were referred to these palliative care programs by their own will. It has eight palliative care physicians and nine certificated nurses involved in palliative care.

**Subjects**
The selection criteria for patients consisted of the following: (1) a cancer diagnosis, (2) 20 years and older, (3) a fatigue intensity score of four or more on a 0 to 10 NRS, (4) a life expectancy >30 days estimated by palliative care physicians, (5) inpatients undergoing only palliative care, (6) no anticancer treatment plan, (7) a performance status that ranged from 0 to 3, and (8) had provided written informed consent. The patients who had (1) received systemic corticosteroid therapies within one week, (2) received surgery within four weeks, (3) received radical irradiation therapy within two weeks, (4) received antitumor treatment within two weeks, and (5) diabetes mellitus, an active infection, or cognitive disorder were ineligible for this study.

**Treatment methods**
A physician decided on oral or intravenous dexamethasone treatment. The oral treatment was dexamethasone 8 mg once a day in the morning for days 1 to 7 and 4 mg once a day in the morning for days 8 to 14. The intravenous treatment was dexamethasone 6.6 mg once a day in the morning for days 1 to 7 and 3.3 mg once a day in the morning for days 8 to 14. After starting the treatment, a change of administration route was not permitted.

**Measurements**
Patient characteristics were collected from an electronic chart. Each symptom as well as quality of life (QOL) was collected using self-administered questionnaires that included the Functional Assessment of Chronic Illness Therapy (FACIT)-fatigue subscale and Functional Assessment of anorexia/cachexia therapy (FAACT) on days 1, 8, and 15, and the Edmonton symptom assessment system-revised Japanese version (ESASr-J) and fatigue NRS every day, and personalized symptom goal of fatigue (PSG-fatigue) on day 1, and the achievement of PSG-fatigue and patient’s satisfaction toward the protocol treatment on days 3, 8, and 15. Adverse events were evaluated using the Common Terminology Criteria for Adverse Events version 4.0 and Confusion Assessment Method (CAM).

The FACIT-fatigue subscale was developed by FACIT.org and is widely used for evaluation of CRF and was used in a previous RCT. It consists of 13 items using a 0 to 4 Likert scale (0, not at all; 4, very much). FAcCT was also developed by FACIT.org and is widely used for the evaluation of anorexia and cachexia. It consists of 27 general QOL questions (functional assessment of cancer therapy-general), which are divided into 4 domains (physical well-being [PWB], social well-being [SWB], emotional well-being [EWB], and functional well-being [FWB]), and 12 items for the anorexia-cachexia subscale (ACS). These items were evaluated using a 0 to 4 Likert scale (0, not at all; 4, very much).

ESASr-J was used to assess 9 symptoms using a 0 to 10 NRS (0: none–10: worst): 6 physical symptoms (pain, fatigue, nausea, drowsiness, dyspnea, and anorexia), 2 psychological symptoms (depression and anxiety), and well-being. The time frame of ESASr-J was specified as “now.” The fatigue NRS evaluated the average severity of fatigue during the previous 24 hours using 0 to 10 NRS (0: none–10: worst).

PSG-fatigue was assessed by asking the patients, “at what level would you feel comfortable with fatigue?” to identify the maximal symptom intensity they would consider comfortable on a 0 to 10 NRS. The achievement of PSG-fatigue was defined as fatigue intensity from ESASr-J lower than the PSG-fatigue score.

Patient’s satisfaction for the protocol treatment was assessed using a 6-point Likert scale ranging from “strongly disagree” to “strongly agree,” and calculated using the proportion of subjects rated “slightly agree,” “agree,” and “strongly agree” among subjects who completed the questionnaires. CAM is a widely used instrument to identify delirium. Laboratory data within one week from enrollment were obtained from the electronic chart.
Statistical methods
Continuous data were summarized using median (range), mean (±standard deviation), and mean (95% confidence interval [CI]). General linear models that included a time point (day 0, day 1, and day 8) as explanatory variables were used to summarize the longitudinal change of the FACIT-fatigue subscale scores. An unstructured covariance matrix was assumed, and robust standard error was calculated for parameter estimates. The point estimate and 95% CI were calculated for the mean scores at each time point and the difference at day 8 from day 1. When the lower limit of the CI exceeded the threshold of three points, protocol treatment was used. For the purpose to validating the previous results of Yennurajalingam et al. in the present population, the required sample size was calculated to be 32 patients for the study to have a power of 90%, assuming that the expected and threshold average change of FACIT-fatigue subscale score was 8 and 3, respectively; a standard deviation of 8; a one-sided significance level of 0.025; and 10% of cases were ineligible. Point estimates and CI s for the average change of other measurements at each day were calculated. Kaplan–Meier methods were used to show the median period of maximum effect of dexamethasone in ESAS-fatigue and ESAS-lack of appetite.

Results
A total of 32 patients with cancer and an average fatigue intensity of ≥4 were enrolled at five institutes between October 2017 and September 2019. The reasons for excluding patients are shown in Figure 1. A total of 14 patients did not complete the study period: 1 patient withdrew consent before any study procedures were done, 2 withdrew consent during the study period, 1 declined to continue the treatment, 3 discontinued due to adverse events, 3 changed the drug administration route, and 2 discontinued due to disease progression. The patients’ backgrounds, symptoms, and laboratory data at day 1 are given in Table 1.
Table 1. Patients’ Backgrounds

| Variables                                      | N (%) |
|------------------------------------------------|-------|
| Age, median (range)                            | 65.5 (39–83) |
| Gender                                         |       |
| Male                                           | 18 (56.3) |
| Female                                         | 14 (43.7) |
| Performance status                             |       |
| 0–1                                            | 0 (0) |
| 2                                              | 6 (18.8) |
| 3                                              | 25 (81.2) |
| Primary tumor site                             |       |
| Colorectal                                     | 9 (29) |
| Lung                                           | 16 (51.6) |
| Esophagus                                      | 5 (16.1) |
| Pancreas                                       | 3 (9.7) |
| Liver and bile duct                            | 2 (6.5) |
| Ovary and uterus                               | 2 (6.5) |
| Breast                                         | 1 (3.2) |
| Stomach                                        | 1 (3.2) |
| Bone and soft tissue                           | 1 (3.2) |
| Other                                          | 2 (6.5) |
| Distant metastasis                             |       |
| Lymph node                                     | 16 (51.6) |
| Lung                                           | 12 (38.7) |
| Liver                                          | 9 (29.0) |
| Bone                                           | 9 (29.0) |
| Brain                                          | 1 (3.2) |
| Symptom measures                               |       |
| FACIT-fatigue subscale                         | 15.5 (11.5) |
| Fatigue NRS                                     | 6.5 (2.3) |
| FACT-G                                         | 50.2 (12.5) |
| PWB                                            | 9.6 (5.0) |
| SWB                                            | 18.1 (5.6) |
| EWB                                            | 12.6 (5.0) |
| FBW                                            | 9.9 (5.0) |
| ACS                                            | 20.8 (8.7) |
| FAACT total                                     | 71 (24.2) |
| FAACT TOI                                      | 40.3 (14.4) |
| ESAS pain                                       | 4.1 (3.4) |
| ESAS tiredness                                 | 5.7 (3.1) |
| ESAS drowsiness                                | 5.0 (3.1) |
| ESAS nausea                                    | 2.4 (3.1) |
| ESAS lack of appetite                           | 5.8 (3.7) |
| ESAS shortness of breath                       | 3.7 (3.7) |
| ESAS depression                                | 3.9 (3.1) |
| ESAS anxiety                                   | 4.6 (3.1) |
| ESAS well-being                                | 6.2 (2.5) |
| ESAS physical distress score                   | 26.7 (15.0) |
| ESAS psychological distress score              | 8.5 (5.6) |
| ESAS symptom distress score                    | 41.4 (21.2) |
| Laboratory data                                |       |
| Albumin (g/dL)                                 | 2.6 (0.7) |
| White blood cell (×100/μL)                     | 110.3 (74.0) |
| Hemoglobin (g/dL)                              | 103.1 (1.5) |
| Platelet (×10,000/μL)                          | 333.3 (15.5) |
| C-reactive protein (mg/dL)                     | 7.6 (5.5) |
| Aspartate aminotransferase (IU/L)              | 35 (20) |
| Alanine aminotransferase (IU/L)                | 19 (12) |
| Total bilirubin (mg/dL)                        | 0.58 (0.32) |
| Creatinin (mg/dL)                              | 0.82 (0.34) |

Data are in n (%) or mean (SD) unless reported otherwise.

ACS, anorexia-cachexia subscale; ESAS, Edmonton symptom assessment system; EWB, emotional well-being; FAACT, functional assessment of anorexia-cachexia therapy; FACT-G, functional assessment of chronic illness therapy; FACT-G, functional assessment of cancer therapy-general; FWB, functional well-being; NRS, numeric rating scale; PWB, physical well-being; SWB, social well-being; TOI, trial outcome index.

Treatment effect on fatigue

At day 8, the mean FACIT-fatigue subscale score significantly improved [mean change 5.2 (95% CI 0.8–10.0), p = 0.02] (Table 2). However, this study failed to achieve the preset efficacy because the lower threshold of average change of FACIT-fatigue subscale was lower than 3.0 (p = 0.72). Both fatigue NRS and ESAS-fatigue were significantly improved at day 3 [1.11 (−2.0 to 0.2), p = 0.01 and −1.3 (−2.3 to −0.2), p = 0.02, respectively], but these efficacies were not shown at day 8 [−0.76 (−1.8 to 0.3), p = 0.16 and −0.5 (−1.7 to 0.6), p = 0.38, respectively] and at day 15 [−0.63 (−1.8 to 0.5), p = 0.28 and −0.2 (−1.5 to 1.0), p = 0.71, respectively]. The achievement of PSG-fatigue was 17.9%, 25.9%, and 18.8% at days 3, 8, and 15, respectively. Overall satisfaction with treatment was 73.1%, 66.7%, and 75.0% at days 3, 8, and 15, respectively. Ad hoc analysis showed that the median period of maximum effect for fatigue was day 5 (95% CI days 4–9).

Other symptoms

ESAS-lack of appetite significantly improved at day 3 [−1.9 (−3.1 to −0.7), p < 0.01] and this improvement continued to day 8 [−1.6 (−2.9 to −0.2), p = 0.02] and day 15 [−1.7 (−3.3 to −0.1), p = 0.04]. Ad hoc analysis showed that the median period of maximum effect for lack of appetite was day 4 (95% CI days 3–6). ESAS-pain improved at day 3 [−1.2 (−2.1 to −0.3), p = 0.01] and day 8 [−1.3 (−2.3 to −0.3), p = 0.02]. ESAS-anxiety and ESAS-well-being improved at day 3 [−1.3 (−2.3 to −0.2), p = 0.02, and −1.8 (−2.6 to −1.0), p < 0.01, respectively]. Ad hoc analysis showed that the median period of maximum effect for lack of appetite was day 4 (95% CI days 3–6).

Quality of life

ACS had significantly improved at day 8 [5.6 (2.5–8.8), p < 0.001] and day 15 [5.2 (0.6–9.7), p = 0.03]. PWB had also significantly improved at day 8 [3.3 (1.0–5.5), p < 0.01] and day 15 [2.9 (0.7–5.1), p < 0.01]. However, SWB, EWB, and FWB did not improve.

Adverse events

A total of 29 adverse events occurred (Table 3). Among them, seven were severe adverse events with a grade of 3 or 4 (fatigue n = 3, delirium n = 1, hyperglycemia n = 1, anemia n = 1, and insomnia n = 1). The patients with fatigue and delirium died because of disease progression. None of the adverse events were suspected to...
have been caused by the study medication. CAM identified one patient until day 8 and four patients until day 15 with delirium.

**Discussion**

This study showed that dexamethasone 8 mg for CRF in inpatients without an antitumor treatment plan failed to achieve preset efficacy, which we defined as the placebo effect using the criteria of the previous RCT. Dexamethasone 8 mg improved FACIT-fatigue subscale, lack of appetite, ACS, and PWB. In addition, adverse events were tolerable.

**Table 3. Adverse Events in Dexamethasone Treatment**

| All grades | Grade 3 or 4 |
|------------|--------------|
| N (%)      | N (%)        |
| Delirium   | 2 (6.5)      | 1 (3.2) |
| Gastric hemorrhage | 1 (3.2) | 0 (0) |
| Cough      | 1 (3.2)      | 0 (0)  |
| Generalized muscle weakness | 1 (3.2) | 0 (0) |
| Somnolence | 6 (19.4)     | 0 (0)  |
| Hyperglycemia | 2 (6.5) | 1 (3.2) |
| Hyperphosphatemia | 1 (3.2) | 0 (0) |
| Fatigue    | 3 (9.7)      | 3 (9.7) |
| Anemia     | 1 (3.2)      | 1 (3.2) |
| Insomnia   | 10 (32.3)    | 1 (3.2) |
| Edema limbs| 1 (3.2)      | 0 (0)  |
| Total      | 29           | 7      |

* *; < 0.05 compared to baseline.

The most important finding was that the efficacy of dexamethasone for CRF was decreased among this study population compared with the previous RCT. The efficacy of dexamethasone may vary depending on the patients’ general condition. Among this study population, three-quarters of participants were performance status (PS) 3 and mean C-reactive protein (CRP) was high (7 mg/dL). In contrast, the previous RCT included no information about PS, FWB, or laboratory data. In addition, the general condition in the previous RCT may be better than those in this study population because patients who received any treatment were eligible and the FACIT-fatigue subscale at baseline was higher than that in this study. In contrast, Miura et al. reported similar FACIT-fatigue subscale and CRP level scores to the inpatients in our palliative care unit (PCU) (data not shown). Matsu et al. reported that systemic corticosteroids (mean betamethasone: 2.4 mg/day) improved fatigue NRS score by 1.9, which was greater than those in this study. This study excluded patients with PS 4, which was associated with nonresponse to systemic corticosteroids. However, the change of fatigue NRS in this study was lower. The mentioned differences may be due to the data collection method as this study used self-administered questionnaires, which the other studies
Steroid therapy. Under inflammation-induced regulated repression or resistance to the effect of corticosteroid therapy. Under inflammation-induced regulated repression or resistance to the effect of corticosteroid therapy. Therefore, this study population may be under severe and continuous inflammatory conditions, compared with that study. Newton et al. reported that glucocorticoid and cytokine crosstalk regulated repression or resistance to the effect of corticosteroid therapy. Under inflammation-induced oxidative stress, the decrease of the activity and expression of histone deacetylase-2, which was needed to activate inflammatory genes, becomes resistant to the anti-inflammatory actions of glucocorticoids.

In this study population, the short-term administration of high-dose dexamethasone improved ACS scores as well as lack of appetite and PWB, and did not affect patients’ FWB. The present results are similar to previous RCTs using dexamethasone 8 mg or methylprednisolone (mPSL) 32 mg; however, these studies did not set appetite as a primary endpoint. This study found that the median period of maximum effect for appetite was day 4, which was shorter than that for fatigue (day 5). Thus, appetite may be more responsive to corticosteroid therapy than fatigue. However, even if high-dose dexamethasone stimulates the patient’s appetite, dexamethasone should be gradually decreased, as muscle weakness and atrophy are well-known side effects of systemic corticoid treatments. Considering the long-term effects, improving muscle strength and muscle mass may require a combination of appetite stimulants, such as short-term administration of high-dose dexamethasone, and anticachexic agents, such as anamoreline, in future trials. The effect of dexamethasone and anamoreline as appetite stimulants could enable advanced cancer patients to keep living in their own home with home-based palliative care.

This study has several limitations. The first is limitations regarding generalization. This study had strict criteria for inclusion and exclusion. Therefore, it took 2.2 years to enroll 32 participants. The second is sampling methods. This study had convenient sampling and not continuous sampling; therefore, the reasons why patients were ineligible were not investigated. The third is a high attrition rate. This study showed 43.8% of subjects did not complete a two-week study protocol. Whereas the inpatients undergoing only palliative care might not use. The differences may also be explained by inflammatory status as the levels of CRP and albumin in that study were 5 mg/dL and 2.8 g/dL, respectively, which were lower and higher than those in this study. Albumin level is considered as an inflammatory marker because inflammation stimulates hepatocytes to increase acute phase protein synthesis and to decrease albumin synthesis. Therefore, this study population may be under severe and continuous inflammatory conditions, compared with that study. Newton et al. reported that glucocorticoid and cytokine crosstalk regulated repression or resistance to the effect of corticosteroid therapy. Under inflammation-induced oxidative stress, the decrease of the activity and expression of histone deacetylase-2, which was needed to activate inflammatory genes, becomes resistant to the anti-inflammatory actions of glucocorticoids.

Conclusions
This study failed to achieve the preset efficacy. However, dexamethasone 8 mg improved fatigue, appetite, ACS, and PWB, and was tolerable among inpatients undergoing only palliative care. This treatment may be an option for inpatients with moderate CRF.

Acknowledgments
The authors thank all participants, their families, and all research group members. This study was supported by the Clinical Research Support Office in NCCE, Japan, and by the Japan Supportive, Palliative, and Psychosocial Oncology Group.

Authors’ Contributions
T.M., A.O., E.S., A.I., and T.Y. designed the study. T.M., H.H., E.S., K.T., K.I., T.K., H.S., H.I., and A.I. recruited patients. T.Y. was involved in analysis. T.M., A.O., T.Y., E.S., and A.I. interpreted data. All authors were involved in drafting and approval of the article.
Ethical Statement
The National Cancer Center Hospital East Certified Review Board (CRB3180009) approved the study.

Funding Information
The Japan Agency for Medical Research and Development provided funding for this study (16ck0106217h0001).

Author Disclosure Statement
No competing financial interests exist.

References
1. Rao A, Cohen HJ: Symptom management in the elderly cancer patient: Fatigue, pain, and depression. J Natl Cancer Inst Monogr 2004;2004: 150–157.
2. Morita T, Sakaguchi Y, Hirai K, et al.: Desire for death and requests to hasten death of Japanese terminally ill cancer patients receiving specialized inpatient palliative care. J Pain Symptom Manage 2004;27: 44–52.
3. Okuyama T, Akechi T, Kugaya A, et al.: Development and validation of the cancer fatigue scale: A brief, three-dimensional, self-rating scale for assessment of fatigue in cancer patients. J Pain Symptom Manage 2000;19:15–14.
4. Mustian KM, Alfano CM, Heckler C, et al.: Comparison of pharmaceutical, psychological, and exercise treatments for cancer-related fatigue: A meta-analysis. JAMA Oncol 2017;3:961–968.
5. Yennurajalingam S, Frisbee-Hume S, Palmer JL, et al.: Reduction of cancer-related fatigue with dexamethasone. A double-blind, randomized, placebo-controlled trial in patients with advanced cancer. J Clin Oncol 2013;31:3076–3082.
6. Paulsen Ø, Klepadl P, Rosland JH, et al.: Efficacy of methylprednisolone on pain, fatigue, and appetite loss in patients with advanced cancer using opioids: A randomized, placebo-controlled, double-blind trial. J Clin Oncol 2014;32:3221–3228.
7. Matsuo N, Morita T, Matsuda Y, et al.: Predictor of responses to corticosteroids for cancer-related fatigue in advanced cancer patients: A multicenter, prospective, observational study. J Pain Symptom Manage 2016;52:64–72.
8. Minton O, Richardson A, Sharpe M, et al.: A systematic review and meta-analysis of the pharmacological treatment of cancer-related fatigue. J Natl Cancer Inst 2008;100:1155–1166.
9. Minton O, Richardson A, Sharpe M, et al.: Drug therapy for the management of cancer-related fatigue. Cochrane Database Syst Rev 2010: CD006704.
10. Temel JS, Abernethy AP, Cunrow DC, et al.: Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): Results from two randomised, double-blind, phase 3 trials. Lancet Oncol 2016;17:519–531.
11. Yokomichi N, Morita T, Nitto A, et al.: Validation of the Japanese version of the edmonton symptom assessment system-revised. J Pain Symptom Manage 2015;50:718–723.
12. Hui D, Park M, Shamieh O, et al.: Personalized symptom goals and response in patients with advanced cancer. Cancer 2016;122:1774–1781.
13. Tagami K, Kawaguchi T, Miura T, et al.: The association between health-related quality of life and achievement of personalized symptom goal. Supportive Care in Cancer 2020;28:4737–4743.
14. Inouye SK, Schlesinger MJ, Lydon TJ: Delirium: A symptom of how hospital care is failing older persons and a window to improve quality of hospital care. Am J Med 1999;106:565–573.
15. Miura T, Matsumoto Y, Kawaguchi T, et al.: Low phase angle is correlated with worse general condition in patients with advanced cancer. Nutr Cancer 2019;71:83–88.
16. Evans DC, Corkins MR, Malone A, et al.: The use of visceral proteins as nutrition markers: An ASPEN position paper. Nutr Clin Pract 2021;36: 22–28.
17. Newton R, Shah S, Altonsoy MO, Gerber AN: Glucocorticoid and cytokine cross-talk: Feedback, feedforward, and co-regulatory interactions determine repression or resistance. J Biol Chem 2017;292:7163–7172.
18. Barnes PJ: Mechanisms and resistance in glucocorticoid control of inflammation. J Steroid Biochem Mol Biol 2010;120:76–85.
19. Ronchetti S, Migliorati G, Brusco S, Riccardi C: Defining the role of glucocorticoids in inflammation. Clin Sci 2018;132:1529–1543.
20. Dubois-Camacho K, Ottun PA, Franco-Muñoz D, et al.: Glucocorticosteroid therapy in inflammatory bowel diseases: From clinical practice to molecular biology. World J Gastroenterol 2017;23:6628.
21. Schakman Q, Kalista S, Barbé C, et al.: Glucocorticoid-induced skeletal muscle atrophy. Int J Biochem Cell Biol 2013;45:2163–2172.